A "productive" meeting with the FDA has given the firm confidence in its regulatory filing and commercialization plans for ST-920.

Sangamo Therapeutics, Inc. , a genomic medicine company, today announced important derisking events in the pathway to a planned BLA submission for isaralgagene civaparvovec, or ST-920, its wholly ...